Copaxone co-packaged with recalled alcohol prep padsMS drug co-packaged in kit containing recalled alcohol prep pads. Arthritis biologics may cut Alzheimer’s risk Thanks for the memory clinic Family doctor finds a better way to treat dementia patients in primary care The ‘real’ Alzheimer’s gene steps forward Prevention trial enrolls patients identified as high-risk for late-onset disease by genetic testing Vimpat: new antiepileptic for partial seizures UCB Canada is introducing Vimpat as adjunctive therapy in the management of epilepsy. Peoples’ jobs linked to area of brain degeneration For physicians with a patient presenting with signs of dementia, the person’s career path may provide clues about their brain health. ‘Destination amnesia’ could impair patient encounters Facing autism A focus on diagnosis, current controversies and proven treatments. First oral MS drug approved in U.S. Fingolimod (Gilenya, Novartis) offers patients an alternative to injectable therapies. Two Canadian centres win stroke care honours Calgary, Toronto Rehab earn new accreditation First Previous 43 44 45 46 47 Next Last
